Per Protocol Analysis is a method of analyzing clinical trial data that includes only participants who fully complied with the study protocol. This approach focuses on evaluating the treatment effect under ideal conditions, considering only those subjects who adhered to all aspects of the trial design. It excludes participants who deviated from the protocol, such as those who dropped out or did not follow the prescribed intervention.
The primary purpose of Per Protocol Analysis is to assess the efficacy of a treatment when administered exactly as intended. While this method can provide insights into the maximum potential benefit of an intervention, it may not reflect real-world effectiveness due to its selective nature. Per Protocol Analysis is often conducted alongside Intent-to-Treat analysis to provide a comprehensive understanding of trial results.
Per Protocol Analysis is crucial in clinical research as it provides a measure of the maximum potential efficacy of a treatment under optimal conditions. This approach helps researchers understand how well an intervention works when administered exactly as intended, which can be valuable for regulatory submissions and determining the best-case scenario for treatment outcomes.
Additionally, Per Protocol Analysis serves as a complementary method to Intent-to-Treat analysis, offering a more complete picture of trial results. By comparing findings from both analyses, researchers can gain insights into the impact of protocol deviations and non-adherence on treatment effectiveness, which is essential for interpreting and generalizing study results to real-world clinical practice.
Axcellant, a specialist global contract research organization (CRO), has been appointed by Switzerland-based Santersus AG to support the execution of…
Axcellant will participate in the Annual Congress of the European Association of Nuclear Medicine (EANM 2026), taking place from 17…
3 Questions with: Prof. Piotr Słomka Large language models are entering nuclear cardiology at a pace that makes the usual…
Copyright @ 2026 Axcellant|Privacy Policy|Cookie Policy|